Security
Ascentage Pharma Group International American Depository Shares · AAPG
AAPGNASDAQotherCurrentCIK 2023311Updated Oct 29, 2026
AAPG price & chart
Loading TradingView…
NASDAQ:AAPG on TradingView ↗About the company
We are a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily in hematological malignancies. For more than two decades, our founders and team have leveraged their deep expertise to develop our proprietary drug discovery platform to pursue particularly challenging targets and significant unmet global medical needs. Our lead assets, olverembatinib and lisaftoclax, have global potential to address the major hematological malignancies, including chronic myeloid leukemia, or CML, acute myeloid leukemia, or AML, chronic lymphocytic leukemia, or CLL, acute lymphocytic leukemia, or ALL, myelodysplastic syndrome, or MDS, and multiple myeloma, or MM, which is expected to exceed US$166 billion in aggregate market size by 2035, according to the industry report commissioned by us and independently prepared by Frost & Sullivan in connection with this offering, or the F&S Report. We are the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators, according to the F&S Report. We have eleven completed or ongoing U.S. and/or internatio…
In the news
CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026 ↗
Recent filings
Show 5 more recent filings
Financials
FY 2024 · USDSource
Source
Source
cash flow · annual statements
| Line item | FY 2024 | FY 2023 |
|---|---|---|
| Cash flows from operating activities: | ||
| Profit or LossUSD | -55,577,000Source | -925,712,000Source |
| Additional Financial Items | ||
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableUSD | 8,597,000Source | -91,537,000Source |
| AdjustmentsForFinanceCostsUSD | 8,830,000Source | 96,057,000Source |
| AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociatesUSD | -38,000Source | 1,076,000Source |
| AdjustmentsForSharebasedPaymentsUSD | 2,867,000Source | 31,503,000Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsUSD | -917,000Source | -1,621,000Source |
| GoodwillUSD | 3,383,000Source | 24,694,000Source |
| InterestPaidClassifiedAsFinancingActivitiesUSD | 8,296,000Source | 92,348,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | 1,153,000Source | 10,766,000Source |
| PaymentsToAcquireOrRedeemEntitysSharesCNY | — | 5,923,000Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesUSD | 73,421,000Source | 953,500,000Source |
| ProceedsFromIssuingSharesUSD | 73,149,000Source | 470,081,000Source |
| ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesCNY | — | 14,000Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesCNY | — | 10,736,000Source |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesUSD | 92,180,000Source | 956,091,000Source |
income statement · annual statements
| Line item | FY 2024 | FY 2023 |
|---|---|---|
| Cost of Goods and Services Sold | —Source | —Source |
| Total RevenueUSD | 134,348,000Source | 221,984,000Source |
| Additional Financial Items | ||
| AdministrativeExpenseUSD | 25,636,000Source | 181,076,000Source |
| BasicEarningsLossPerShareUSD per share | -0.18Source | -3.28Source |
| DeferredTaxExpenseIncomeUSD | 1,428,000Source | -7,150,000Source |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossCNY | -3,881,000Source | -1,517,000Source |
| DepreciationRightofuseAssetsUSD | 1,525,000Source | 1,594,000Source |
| DilutedEarningsLossPerShareUSD per share | -0.18Source | -3.28Source |
| DonationsAndSubsidiesExpenseUSD | 866,000Source | 3,988,000Source |
| ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsedUSD | 33,000Source | 181,000Source |
| ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilitiesUSD | 33,000Source | 181,000Source |
| FinanceCostsUSD | 8,830,000Source | 96,057,000Source |
| GrossProfitUSD | 130,364,000Source | 191,441,000Source |
| IncomeTaxExpenseContinuingOperationsUSD | 1,428,000Source | -7,150,000Source |
| InterestExpenseOnLeaseLiabilitiesUSD | 205,000Source | 1,321,000Source |
| OtherIncomeUSD | 7,858,000Source | 59,316,000Source |
| PostemploymentBenefitExpenseDefinedContributionPlansUSD | 4,713,000Source | 30,705,000Source |
| ProfitLossAttributableToNoncontrollingInterestsUSD | -34,000Source | -75,000Source |
| ProfitLossAttributableToOwnersOfParentUSD | -55,543,000Source | -925,637,000Source |
| ProfitLossBeforeTaxUSD | -54,149,000Source | -932,862,000Source |
| ResearchAndDevelopmentExpenseUSD | 129,772,000Source | 706,972,000Source |
| SellingExpenseUSD | 26,852,000Source | 195,387,000Source |
| ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodUSD | -38,000Source | -38,000Source |
Offerings
Registration 333-297559
Registration 333-284064
- Gross proceeds
- 126356250.0
- Net proceeds
- 117511312.0
- Deal price
- 17.25
- Shares
- 7325000
- Offering price
- $17.25
- Ticker
- AAPG
Filing attachments
ea030994401ex99-1.htm · 6-K · 2026-10-28
Exhibit 99.1 Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. ASCENTAGE PHARMA GROUP INTERNATIONAL 亞盛醫藥集團 (Incorporated in the Cayman Islands with limited liability) (Stock Co…
Read attachment ↗ea030943201ex99-1.htm · 6-K · 2026-10-22
Exhibit 99.1 Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. ASCENTAGE PHARMA GROUP INTERNATIONAL 亞盛醫藥集團 (Incorporated in the Cayman Islands with limited liability) (Stock Co…
Read attachment ↗ea030929901ex99-1.htm · 6-K · 2026-10-21
Exhibit 99.1 Ascentage Pharma’s Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL ROCKVILLE, MD, October 20, 2026 - Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that lisaftoclax (APG-2575), the Company’s novel Bcl-2 inh…
Read attachment ↗ea030929901ex99-2.htm · 6-K · 2026-10-21
Exhibit 99.2 Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. ASCENTAGE PHARMA GROUP INTERNATIONAL 亞盛醫藥集團 (Incorporated in the Cayman Islands with limited liability) (Stock Co…
Read attachment ↗ea030872601ex99-1.htm · 6-K · 2026-10-15
Exhibit 99.1 Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. ASCENTAGE PHARMA GROUP INTERNATIONAL 亞盛醫藥集團 (Incorporated in the Cayman Islands with limited liability) (Stock Co…
Read attachment ↗ea030691901ex99-1.htm · 6-K · 2026-09-29
Exhibit 99.1 Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. ASCENTAGE PHARMA GROUP INTERNATIONAL 亞 盛 醫 藥 集 團 (Incorporated in the Cayman Islands with limited liability) (Sto…
Read attachment ↗